Kaken inks license agreement for STAT6 Inhibitor

27 December 2024

Japanese drugmaker Kaken Pharmaceutical (TYO: 4521) has entered into a license agreement with US healthcare giant Johnson & Johnson (NYSE: JNJ) for the global development, manufacturing and commercialization of a STAT6 program that Kaken is developing.

As a result, Kaken says it will grant J&J an exclusive license for the worldwide development, manufacturing and commercialization of STAT6 program including KP-723, an oral STAT6 inhibitor in preclinical development. Kaken will advance KP-723 to the completion of Phase I clinical trials, after which J&J will conduct the worldwide clinical development and commercialization.

Kaken will retain the commercialization rights in Japan, while J&J will have an option to enter into a co-promotion agreement with Kaken, the company added.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK